European Commission approves Novartis’ Itvisma to treat SMA
RegulatoryapprovedItvismaPositive
AI Analysis
Summary
The European Commission has approved Novartis' Itvisma for treating 5q SMA in children aged 2 years and older, teenagers, and adults with bi-allelic SMN1 gene mutations.
Outcome Details
European Commission approval for children 2 years and older, teenagers, and adults with 5q SMA
Importance:8/10
Sentiment:
0.90
regulatory approvalEuropean CommissionSMArare disease
Related Companies
Read the original article
Published by Pharmaceutical Technology on July 3, 2026 7:21 AM